Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca to Pay Daiichi Sankyo $1B For Rights to Antibody Drug Conjugate DS-1062

NEW YORK – Daiichi Sankyo said on Monday that it has entered into a global development and commercialization agreement with AstraZeneca for its TROP2-targeting antibody drug conjugate DS-1062.

Under the agreement, AstraZeneca will make an upfront payment of $1 billion to Daiichi Sankyo, of which $350 million is due upon execution, $325 million after a year, and $325 million after two years. Additionally, AstraZeneca may also pay up to $6 billion for achievement of regulatory or sales-related milestones.

The companies will jointly develop and commercialize DS-1062 worldwide, sharing in the costs of advancing the drug and in the profits, but Daiichi Sankyo will maintain exclusive rights to the drug in Japan. Daiichi Sankyo will also manufacture and supply DS-1062 under the agreement.

The latest deal builds on the two companies' existing partnership, inked in March 2019, around Daiichi Sankyo's HER2-targeted antibody drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu). AstraZeneca CEO Pascal Soriot said in a statement that his company sees "significant potential" in DS-1062 as a treatment for lung, breast, and other cancers that commonly express TROP2. "We now have six potential blockbusters in oncology with more to come in our early and late pipelines," Soriot added.

DS-1062 comprises an anti-TROP2 monoclonal antibody and a topoisomerase I inhibitor. The drug is currently being studied in a Phase I trial involving non-small cell lung cancer and triple-negative breast cancer patients

In July, Daiichi Sankyo announced a multi-year collaboration with Goustave Roussy in France to study and develop DS-1062 in advanced NSCLC patients who have progressed on anti-PD-1/PD-L1 treatments and platinum-doublet chemotherapy, and identify markers of response and resistance. 

Immunomedics is also developing a TROP2-directed antibody drug conjugate, sacituzumab govitecan-hziy (Trodelvy), which was granted accelerated approval by the US Food and Drug Administration in April for previously treated metastatic triple-negative breast cancer.